Phase I-II study of mitomycin C topical therapy for low-grade, low-stage transitional cell carcinoma of the bladder: An interim report

M. D. DeFuria, R. B. Bracken, D. E. Johnson, M. S. Soloway, C. E. Merrin, L. R. Morgan, H. C. Miller, S. T. Crooke

Research output: Contribution to journalArticlepeer-review

26 Scopus citations

Abstract

Intravesical mitomycin C therapy was administered to 63 patients with noninvasive bladder carcinoma in a phase I-II study. Doses ranged from 20 to 60 mg once a week for 8 weeks. The overall response rate was 67% including a complete remission rate of 45%. The median duration of complete remission for the two lowest dose groups was > 14 months, with a range of 1-36+ months. Followup is not yet adequate to determine the median duration of complete remission for the higher dose groups. No bone marrow suppression or other systemic toxic effects were noted. Adverse effects were localized and occurred infrequently. No mitomycin C was detected in serial serum samples after intravesical instillation.

Original languageEnglish (US)
Pages (from-to)225-230
Number of pages6
JournalCancer Treatment Reports
Volume64
Issue number2-3
StatePublished - Nov 18 1980

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase I-II study of mitomycin C topical therapy for low-grade, low-stage transitional cell carcinoma of the bladder: An interim report'. Together they form a unique fingerprint.

Cite this